Loading stock data…
Arvinas (ARVN)
$8.40+0.40 (+5.00%)
Market OpenUpdated 2:06 PM EDT
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Arvinas, Inc. in the Healthcare sector is trading at $8.40 with a market capitalization of $473M. Wall Street consensus targets $14.80 (15 analysts), implying a +76.2% move over the next 12 months. The stock is currently 42% below its 52-week high of $14.51, remaining 21.3% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 77 is overbought against a weak tape. The Whystock Score of 20/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +76.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Overbought RSI 77 against a weak tape — risk of pullback
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $15.60M↑ | $9.50M↓ | $41.90M↑ | $22.40M↓ | $188.80M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$63.80M↑ | -$74.60M↓ | -$43.80M↑ | -$71.50M↓ | $71.40M |
| Net Income | -$57.60M↑ | -$67.40M↓ | -$35.10M↑ | -$61.20M↓ | $82.90M |
Peer Comparison
JNJUNHPFE
Fundamentals
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degrad...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$472.94M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-57.21%
Volume
Today's trading volume
399,407
Recent News
uniQure (QURE) Soars 78.4%: Is Further Upside Left in the Stock?
uniQure (QURE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Twist Bioscience (TWST) Surges 9.3%: Is This an Indication of Further Gains?
Twist Bioscience (TWST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Arvinas Sharpens Pipeline Focus After First PROTAC Approval, Eyes Key Trial Data
Arvinas (NASDAQ:ARVN) management outlined a more selective development strategy at a Jefferies-hosted investor discussion, emphasizing internal investment in neurological and oncology programs where the company believes it can create differentiated therapies, while seeking partners for assets that m
Bullish: Analysts Just Made A Noticeable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts
Celebrations may be in order for Arvinas, Inc. ( NASDAQ:ARVN ) shareholders, with the analysts delivering a significant...
Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer
Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) stock is trading higher on Tuesday as the company is entering an exclusive global licensing agreement with Arvinas Inc. (NASDAQ:ARVN) and Pfizer Inc. (NYSE:PFE) for its oral PROTAC drug, VEPPANU (vepdegestrant). This news comes as the...